367 related articles for article (PubMed ID: 31706025)
1. Proteomic characterization of Mycobacterium tuberculosis reveals potential targets of bostrycin.
Yuan P; He L; Chen D; Sun Y; Ge Z; Shen D; Lu Y
J Proteomics; 2020 Feb; 212():103576. PubMed ID: 31706025
[TBL] [Abstract][Full Text] [Related]
2. Identification of Bostrycin Derivatives as Potential Inhibitors of Mycobacterium tuberculosis Protein Tyrosine Phosphatase (MptpB).
Chen DN; Chen H; She ZG; Lu YJ
Med Chem; 2016; 12(3):296-302. PubMed ID: 26434800
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic Signatures Predict Regulators of Drug Synergy and Clinical Regimen Efficacy against Tuberculosis.
Ma S; Jaipalli S; Larkins-Ford J; Lohmiller J; Aldridge BB; Sherman DR; Chandrasekaran S
mBio; 2019 Nov; 10(6):. PubMed ID: 31719182
[TBL] [Abstract][Full Text] [Related]
6. An
Kumar S; Sahu P; Jena L
Int J Mycobacteriol; 2019; 8(3):252-261. PubMed ID: 31512601
[TBL] [Abstract][Full Text] [Related]
7. Proteome-wide subtractive approach to prioritize a hypothetical protein of XDR-Mycobacterium tuberculosis as potential drug target.
Uddin R; Siddiqui QN; Sufian M; Azam SS; Wadood A
Genes Genomics; 2019 Nov; 41(11):1281-1292. PubMed ID: 31388979
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of potential druggable targets among hypothetical proteins of extensively drug resistant Mycobacterium tuberculosis (XDR KZN 605) through subtractive genomics approach.
Uddin R; Siddiqui QN; Azam SS; Saima B; Wadood A
Eur J Pharm Sci; 2018 Mar; 114():13-23. PubMed ID: 29174549
[TBL] [Abstract][Full Text] [Related]
9. Identification of TB-E12 as a novel FtsZ inhibitor with anti-tuberculosis activity.
Lin Y; Zhang H; Zhu N; Wang X; Han Y; Chen M; Jiang J; Si S
Tuberculosis (Edinb); 2018 May; 110():79-85. PubMed ID: 29779778
[TBL] [Abstract][Full Text] [Related]
10. Drug repurposing: Fusidic acid as a potential inhibitor of M. tuberculosis FtsZ polymerization - Insight from DFT calculations, molecular docking and molecular dynamics simulations.
Akinpelu OI; Lawal MM; Kumalo HM; Mhlongo NN
Tuberculosis (Edinb); 2020 Mar; 121():101920. PubMed ID: 32279872
[TBL] [Abstract][Full Text] [Related]
11. Docking- and pharmacophore-based virtual screening for the identification of novel Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB) inhibitor with a thiobarbiturate scaffold.
Zhang D; Lin Y; Chen X; Zhao W; Chen D; Gao M; Wang Q; Wang B; Huang H; Lu Y; Lu Y
Bioorg Chem; 2019 Apr; 85():229-239. PubMed ID: 30641319
[TBL] [Abstract][Full Text] [Related]
12. Mycobacterium tuberculosis Low Molecular Weight Phosphatases (MPtpA and MPtpB): From Biological Insight to Inhibitors.
Fanzani L; Porta F; Meneghetti F; Villa S; Gelain A; Lucarelli AP; Parisini E
Curr Med Chem; 2015; 22(27):3110-32. PubMed ID: 26264920
[TBL] [Abstract][Full Text] [Related]
13. Identification of New
Almeleebia TM; Shahrani MA; Alshahrani MY; Ahmad I; Alkahtani AM; Alam MJ; Kausar MA; Saeed A; Saeed M; Iram S
Molecules; 2021 Apr; 26(8):. PubMed ID: 33923734
[No Abstract] [Full Text] [Related]
14. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
15. Assessing the progress of Mycobacterium tuberculosis H37Rv structural genomics.
Fang Z; van der Merwe RG; Warren RM; Schubert WD; Gey van Pittius NC
Tuberculosis (Edinb); 2015 Mar; 95(2):131-6. PubMed ID: 25578513
[TBL] [Abstract][Full Text] [Related]
16. Elucidation of marine fungi derived anthraquinones as mycobacterial mycolic acid synthesis inhibitors: an in silico approach.
Sharma A; Islam MH; Fatima N; Upadhyay TK; Khan MKA; Dwivedi UN; Sharma R
Mol Biol Rep; 2019 Apr; 46(2):1715-1725. PubMed ID: 30715689
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis reveals that sulfamethoxazole induces oxidative stress in M. tuberculosis.
Sarkar R; Mdladla C; Macingwana L; Pietersen RD; Ngwane AH; Tabb DL; van Helden PD; Wiid I; Baker B
Tuberculosis (Edinb); 2018 Jul; 111():78-85. PubMed ID: 30029919
[TBL] [Abstract][Full Text] [Related]
18. Development of ssDNA aptamers as potent inhibitors of Mycobacterium tuberculosis acetohydroxyacid synthase.
Baig IA; Moon JY; Lee SC; Ryoo SW; Yoon MY
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1338-50. PubMed ID: 25988243
[TBL] [Abstract][Full Text] [Related]
19. Identification of fusarielin M as a novel inhibitor of Mycobacterium tuberculosis protein tyrosine phosphatase B (MptpB).
Chen D; Liu L; Lu Y; Chen S
Bioorg Chem; 2021 Jan; 106():104495. PubMed ID: 33293055
[TBL] [Abstract][Full Text] [Related]
20. Comparative Proteomic Analysis of Aminoglycosides Resistant and Susceptible Mycobacterium tuberculosis Clinical Isolates for Exploring Potential Drug Targets.
Sharma D; Kumar B; Lata M; Joshi B; Venkatesan K; Shukla S; Bisht D
PLoS One; 2015; 10(10):e0139414. PubMed ID: 26436944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
